Literature DB >> 25640546

Clinical and economic results of ventriculoperitoneal shunt infections in children.

Ali Kanik1, Seda Sirin, Engin Kose, Kayı Eliacik, Murat Anil, Mehmet Helvaci.   

Abstract

AIM: This study evaluated the clinical and economic outcomes of ventriculoperitoneal shunt infections.
MATERIAL AND METHODS: Patients diagnosed with ventriculoperitoneal shunt infections for the first time between 1 January 2007 and 31 December 2011 were included in this study. Demographic, clinical, and economic data were analyzed retrospectively. A cost coefficient (total cost/follow-up period) and hospitalization coefficient (duration of hospitalization/follow-up period) were calculated for each patient.
RESULTS: In total, 132 shunt infections (mean follow-up, 734 ± 367 days) were evaluated in 51 patients (mean age, 16.6 ± 9.22 months; median age, 3 months; range, 1-88 months; 28 females, 21 males). In 23 patients (45%), shunt infections were seen in the first 2 months following shunt placement. Seven patients died during the follow-up. There was a negative correlation between the age at diagnosis and the hospitalization duration (p = 0.005, r = -0.381). The average cost of hospitalization per patient was 6397 ± 4338 TL. There was a negative correlation between the cost index and the age at diagnosis (p = 0.04, r = -0.292).
CONCLUSION: Ventriculoperitoneal shunt infections have significant medical and economic impacts. Younger the diagnosis of patients, the hospitalization duration and treatment cost were higher.

Entities:  

Mesh:

Year:  2015        PMID: 25640546     DOI: 10.5137/1019-5149.JTN.8540-13.2

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  1 in total

Review 1.  Neuroendoscopic lavage for the treatment of pyogenic ventriculitis in children: personal series and review of the literature.

Authors:  Adalberto Ochoa; Romina Argañaraz; Beatriz Mantese
Journal:  Childs Nerv Syst       Date:  2021-11-13       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.